近日,，來自蒂賓根大學等處的研究者發(fā)表了兩項實驗研究結果，揭示了腎癌的疫苗IMA901的部分研究成果,，相關研究結果已于近日刊登在了國際著名雜志Nature Medicine上,。IMA901常被用來治療腎癌患者，由10種合成性腫瘤相關多肽(TUMAPs)組成,，可以激活機體殺傷T細胞抵御腫瘤的能力,。不像化學療法，以免疫系統(tǒng)為靶點的新療法可以動員免疫系統(tǒng)來攻擊癌癥,，研究揭示了這種抵御癌癥的免疫活性法非常成功,，并且可以延長患者壽命，而且副作用比較小,。
研究者Hans等表示,，這項研究工作是癌癥免疫療法的里程碑，以前所有的用藥療法在抑制腎臟腫瘤生長上有明確的改進,，但是這并不能使得腎癌患者壽命延長,，而且不能治愈疾病。
這項研究揭示了腎癌患者可以攜帶有針對兩個或更多腫瘤相關的肽類,，這樣免疫反應和臨床效應就可以明確的聯(lián)系起來了,。這就再次肯定了癌癥療法可以在未來通過激活免疫效用來實現(xiàn)。
研究論文中,，研究者同樣也描述了他們發(fā)現(xiàn)了生物標記物,，在病人接受IMA901之后如何延長其生存可以給予一個精確的預測。一項超過300個潛在標志物的分析揭示了患者機體的免疫效應以及IMA901治療后病人生命的延長效應,。（生物谷Bioon.com）
編譯自：Kidney Cancer Vaccine Successful in Clinical Trials
doi:10.1038/nm.2883
PMC:
PMID:
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Steffen Walter,1, 21 Toni Weinschenk,1, 21 Arnulf Stenzl,2 Romuald Zdrojowy,3 Anna Pluzanska,4 Cezary Szczylik,5 Michael Staehler,6 Wolfram Brugger,7 Pierre-Yves Dietrich,8 Regina Mendrzyk,1 Norbert Hilf,1 Oliver Schoor,1 Jens Fritsche,1 Andrea Mahr,1 Dominik Maurer,1 Verona Vass,1 Claudia Trautwein,1 Peter Lewandrowski,1 Christian Flohr,1 Heike Pohla,9, 10 Janusz J Stanczak,11 Vincenzo Bronte,12 Susanna Mandruzzato,13, 14 Tilo Biedermann,15 Graham Pawelec,16 Evelyna Derhovanessian,16 Hisakazu Yamagishi,17 Tsuneharu Miki,18 Fumiya Hongo,18 Natsuki Takaha,18 Kosei Hirakawa,19 Hiroaki Tanaka,19 Stefan Stevanovic,20 Jürgen Frisch,1 Andrea Mayer-Mokler,1 Alexandra Kirner,1 Hans-Georg Rammensee,20 Carsten Reinhardt1, 21 & Harpreet Singh-Jasuja1, 21 et al.
IMA901 is the first therapeutic vaccine for renal cell cancer (RCC) consisting of multiple tumor-associated peptides (TUMAPs) confirmed to be naturally presented in human cancer tissue. We treated a total of 96 human leukocyte antigen A (HLA-A)*02+ subjects with advanced RCC with IMA901 in two consecutive studies. In the phase 1 study, the T cell responses of the patients to multiple TUMAPs were associated with better disease control and lower numbers of prevaccine forkhead box P3 (FOXP3)+ regulatory T (Treg) cells. The randomized phase 2 trial showed that a single dose of cyclophosphamide reduced the number of Treg cells and confirmed that immune responses to multiple TUMAPs were associated with longer overall survival. Furthermore, among six predefined populations of myeloid-derived suppressor cells, two were prognostic for overall survival, and among over 300 serum biomarkers, we identified apolipoprotein A-I (APOA1) and chemokine (C-C motif) ligand 17 (CCL17) as being predictive for both immune response to IMA901 and overall survival. A randomized phase 3 study to determine the clinical benefit of treatment with IMA901 is ongoing.
